Northpond Ventures’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

Northpond Ventures’s Portfolio DICE Stock Details DICE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,292,871	Closed	-$94.3M	–	5
2023 Q1	$94.3M	Hold	3,292,871	–	–	53.91%	1
2022 Q4	$103M	Hold	3,292,871	–	–	55.73%	1
2022 Q3	$66.8M	Hold	3,292,871	–	–	46.8%	1
2022 Q2	$51.1M	Hold	3,292,871	–	–	48.67%	1
2022 Q1	$63M	Hold	3,292,871	–	–	33.95%	1
2021 Q4	$83.3M	Buy	+3,292,871	New	+$96.5M	29.17%	2

Other funds holding DICE

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Northpond Ventures's DICE Position: Q2 2023 in Review

Northpond Ventures sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q2 2023, closing a stake of 3,292,871 shares — an estimated $94.3M sold.

Northpond Ventures first reported a position in DICE in Q4 2021 and held it in 6 quarters. The position peaked at $103M in Q4 2022. 160 funds tracked by Wall St. Rank hold DICE as of Q2 2023.

Northpond Ventures reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Northpond Ventures sold 3,292,871 DICE Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $94.3M.
Northpond Ventures first reported a position in DICE Therapeutics, Inc. Common Stock in Q4 2021 and held it in 6 quarters.
Northpond Ventures's DICE Therapeutics, Inc. Common Stock position peaked at $103M in Q4 2022.
160 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Northpond Ventures's 13F filing for Q2 2023, filed 14 Aug 2023.